Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide.

STUDY OBJECTIVES In patients with pulmonary hypertension (PH) secondary to congestive heart failure, inhaled nitric oxide (NO) increases pulmonary vascular smooth-muscle intracellular cyclic guanosine monophosphate (cGMP) concentration, thereby decreasing pulmonary vascular resistance (PVR) and increasing cardiac index (CI). However, these beneficial effects of inhaled NO are limited in magnitude and duration, at least in part due to cGMP hydrolysis by the type 5 isoform of phosphodiesterase (PDE5). The goal of this study was to determine the acute pulmonary and systemic hemodynamic effects of the selective PDE5 inhibitor, sildenafil, administered alone or in combination with inhaled NO in patients with congestive heart failure and PH. DESIGN Single center, case series, pharmacohemodynamic study. SETTING Cardiac catheterization laboratory of a tertiary care academic teaching hospital. PATIENTS We studied 11 patients with left ventricular systolic dysfunction due to coronary artery disease or idiopathic dilated cardiomyopathy who had PH. INTERVENTIONS We administered oral sildenafil (50 mg), inhaled NO (80 ppm), and the combination of sildenafil and inhaled NO during right-heart and micromanometer left-heart catheterization. MEASUREMENTS AND RESULTS Sildenafil administered alone decreased mean pulmonary artery pressure by 12 +/- 5%, PVR by 12 +/- 5%, systemic vascular resistance (SVR) by 13 +/- 6%, and pulmonary capillary wedge pressure by 12 +/- 7%, and increased CI by 14 +/- 5% (all p < 0.05) [+/- SEM]. The combination of inhaled NO and sildenafil decreased PVR by 50 +/- 4%, decreased SVR by 24 +/- 3%, and increased CI by 30 +/- 4% (all p < 0.01). These effects were greater than those observed with either agent alone (p < 0.05). In addition, sildenafil prolonged the pulmonary vasodilator effect of inhaled NO. Administration of sildenafil alone or in combination with inhaled NO did not change systemic arterial pressure or indexes of myocardial systolic or diastolic function. CONCLUSIONS PDE5 inhibition with sildenafil improves cardiac output by balanced pulmonary and systemic vasodilation, and augments and prolongs the hemodynamic effects of inhaled NO in patients with chronic congestive heart failure and PH.

[1]  W. Seeger,et al.  Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial , 2002, The Lancet.

[2]  N. Pereira,et al.  Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. , 2002, The American journal of cardiology.

[3]  E. Bocchi,et al.  Sildenafil Effects on Exercise, Neurohormonal Activation, and Erectile Dysfunction in Congestive Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Study Followed by a Prospective Treatment for Erectile Dysfunction , 2002, Circulation.

[4]  E. Michelakis,et al.  Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial Hypertension: Comparison With Inhaled Nitric Oxide , 2002, Circulation.

[5]  D. Kass,et al.  Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failure , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  N. Morrell,et al.  Sildenafil Inhibits Hypoxia-Induced Pulmonary Hypertension , 2001, Circulation.

[7]  R. Kacmarek,et al.  Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemodynamics and right ventricular contractility in patients with chronic pulmonary hypertension. , 2001, Chest.

[8]  W. Colucci,et al.  Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. , 2000, Circulation.

[9]  S. Gottlieb,et al.  Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. , 2000, Circulation.

[10]  W. Zapol,et al.  Sildenafil Is a Pulmonary Vasodilator in Awake Lambs with Acute Pulmonary Hypertension , 2000, Anesthesiology.

[11]  W. Grossman.  Evaluation of Systolic and Diastolic Function of the Ventricles and Myocardium , 2000 .

[12]  W. Hurford,et al.  Inhaled nitric oxide: basic biology and clinical applications. , 1999, Anesthesiology.

[13]  A. Atz,et al.  Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. , 1999, Anesthesiology.

[14]  J. Corbin,et al.  Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. , 1999, The American journal of cardiology.

[15]  W. Zapol,et al.  Inhaled nitric oxide improves exercise capacity in patients with severe heart failure and right ventricular dysfunction. , 1998, The American journal of cardiology.

[16]  Fumito Ichinose,et al.  Selective Pulmonary Vasodilation Induced by Aerosolized Zaprinast , 1998, Anesthesiology.

[17]  G. Couper,et al.  Influence of inhaled nitric oxide on systemic flow and ventricular filling pressure in patients receiving mechanical circulatory assistance. , 1997, Circulation.

[18]  P. Hunziker,et al.  Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure , 1995, The Lancet.

[19]  M. Mathier,et al.  Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. , 1995, Journal of the American College of Cardiology.

[20]  J. Loscalzo,et al.  Cardiovascular Effects of Inhaled Nitric Oxide in Patients With Left Ventricular Dysfunction , 1994, Circulation.

[21]  R. Kacmarek,et al.  Hemodynamic effects of inhaled nitric oxide in heart failure. , 1994, Journal of the American College of Cardiology.

[22]  S. Lundin,et al.  Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. , 1994, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.